NEW YORK, Sept. 19, 2019 — LMG Life Sciences has awarded King & Spalding its Hatch-Waxman Impact Case of the Year honor for its successful representation of Galderma Laboratories LP in the Galderma Laboratories v. Amneal Pharmaceuticals patent infringement case.
King & Spalding employed an innovative argument that an infringer’s proposed attempt at a design-around product nonetheless infringed under the equitable Doctrine of Equivalents. This helped Galderma earn a favorable ruling that Amneal’s proposed generic version of Galderma’s flagship rosacea drug Oracea infringed five of Galderma’s patents.
Partners Gerald Flattmann, Evan Diamond and Vanessa Yen — who led the Galderma team — accepted the award on behalf of the firm at a ceremony on Sept. 18 in New York City.
The LMG Life Sciences Awards honor firms, individuals and companies behind the most innovative and challenging life sciences work. The publication bases its research on online surveys and interviews with lawyers across the United States. Its researchers also speak to clients and leading lawyers within the industry and review public information to inform their decisions.
About King & Spalding
Celebrating more than 130 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with 1,100 lawyers in 20 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality, and dedication to understanding the business and culture of its clients. More information is available at www.kslaw.com.